key: cord-0023002-gpp2bh1h authors: Gołębiewska, Justyna Eliza; Bryl, Ewa; Daca, Agnieszka; Chamienia, Andrzej; Świętoń, Dominik; Dębska-Ślizień, Alicja title: Achromobacter denitrificans pneumonia in a kidney transplant recipient – dose-dependent decrease of phagocytic activity as a potential mechanism for everolimus pulmonary toxicity date: 2021-09-28 journal: Cent Eur J Immunol DOI: 10.5114/ceji.2021.108762 sha: 8c4ae387fe6ead86b4aef1377d6127ad1de9f7ed doc_id: 23002 cord_uid: gpp2bh1h Mammalian target of rapamycin (mTOR) inhibitors inclusive regimens are associated with increased risk of pulmonary toxicity, but the underlying mechanism has not been elucidated so far. We present the case of a 68-year-old man, after deceased-donor kidney transplantation (KTx), maintained on de novo everolimus (EVR) based immunosuppression, who developed Achromobacter denitrificans pneumonia 3 months after KTx. There was clinical improvement with antibiotic treatment, but without a radiological resolution. An additional reduction of the EVR dose resulted only in partial resolution of radiological abnormalities. We performed a functional analysis of peripheral blood neutrophils and monocytes. The ability of phagocytosis and oxidative burst generation against A. denitrificans and Escherichia coli was significantly decreased on EVR treatment as compared to the control healthy person, and significantly improved after 3 weeks of EVR absence. Additionally, these processes were significantly affected by increasing doses of EVR in vitro in the control healthy donor in a dose-dependent manner. EVR discontinuation, with no additional antibiotic treatment, resulted in complete recovery and resolution of pulmonary infiltrates. Our findings suggest that dose-dependent impairment of neutrophil/monocyte phagocytic activity and oxidative burst generation might be a potential mechanism for EVR pulmonary toxicity. The mammalian target of rapamycin (mTOR) inhibitors sirolimus and everolimus (EVR) are immunosuppressive drugs commonly used in renal transplantation. mTOR inhibitors have antiangiogenic and antineoplastic properties, and therefore are associated with a lower risk of malignancy than other immunosuppressive agents. Reduced incidence of cytomegalovirus and BK virus (BKV) infections in kidney transplant (KTx) recipients receiving EVR were also reported [1, 2] . Pulmonary adverse effects are relatively common in KTx recipients treated with mTOR inhibitors with a reported frequency of 2-11% and the onset of symptoms between 1 and 51 months after the initiation of therapy [3] . Several distinct types of pulmonary damage have been recognized, including lymphocytic interstitial pneumonitis, lymphocytic alveolitis, bronchiolitis obliterans with organizing pneumonia, focal pulmonary fibrosis, and even diffuse alveolar hemorrhage [3] [4] [5] . At the onset of this complication, patients with mTOR inhibitor-associated pneumonitis usually present with a cough and/or dyspnea and/or respiratory insufficiency, and sometimes with systemic symptoms such as fever and fatigue. Occasionally, only changes on high-resolution computed tomography (HRCT) scans are observed, with no accompanying clinical symptoms. The most common on HRCT scans are ground-glass opacities, inter-/intra-lobular septal linear thickening, or multifocal areas of parenchymal lung consolidation with a basilar predominance [3] [4] [5] . Also rare cases of opportunistic pulmonary infections, Pneumocystis jiroveci pneumonia and invasive pulmonary aspergillosis, mimicking typical noninfectious mTOR inhibitor-induced pulmonary adverse events, were reported in both EVR and temsirolimus treated patients [6] [7] [8] . Even though both the clinical symptoms and radiological signs have been well described, the etiopathogenic mechanism of mTOR-inhibitor-associated pulmonary toxicity is still unclear. A 68-year-old man with end-stage renal disease of unknown etiology underwent a KTx from a 32-year old deceased female donor, who died of head trauma (cytomegalovirus D-/R+, Epstein-Barr virus D+/R+). He had a past history of type 2 diabetes, hypertension, coronary artery disease and squamous cell carcinoma of the tibial area resected 8 years before the KTx. His past medical history also included pulmonary tuberculosis. He had been maintained on haemodialysis for the preceding seven years. At the time of KTx he was in a good general condition. HLA mismatching was 0 : 1 : 0 (A, B, DR), respectively. Anesthesia and surgery were uneventful, with good initial kidney perfusion. He underwent basiliximab induction therapy and commenced EVR, cyclosporine (CsA) and prednisone maintenance therapy. EVR was introduced because of the history of squamous cell carcinoma. CsA was chosen over tacrolimus in order to prevent significant deterioration of glycemic control in a patient with type 2 diabetes. The doses of EVR and cyclosporine were adjusted to maintain standard target trough levels. The chest X-ray performed on the day of KTx showed no obvious abnormality. Three months later the patient presented with fever, progressive dyspnea, and a productive cough for two weeks. On general examination, the patient was conscious and well-oriented. He had a pulse rate of 108/min, lood pressure of 100/60 mmHg, respiratory rate of 28 cycles/ min and there was evident cyanosis. Room air oxygen saturation was around 90%. Other systemic examinations were normal. Admission chest radiography showed patchy infiltrates suggestive of bacterial pneumonia in the left inferior segments corresponding to crackles, rhonchi and wheezes on auscultation. His laboratory testing revealed a white blood cell (WBC) count of 15.8 × 10 9 /l, hemoglobin 11 g/dl, platelet count 216 × 10 9 /l, absolute neutrophil count 14.9 × 10 9 /l, absolute lymphocyte count 0.32 × 10 9 /l, and C-reactive protein (CRP) 281 mg/l. Kidney function was stable with serum creatinine of 0.92 mg/dl and MDRD eGFR on admission > 60 ml/min/1.73 m 2 . The EVR level was 7.1 ng/ml and cyclosporine level 150 ng/ml (Table 1) . He initially received amoxicillin/clavulanic acid. Bacterial cultures of blood and urine were negative. The symptoms improved, and fever resolved, with a decrease in both WBC and CRP levels over the next few days with empiric antibiotic treatment. There was clinical improvement, but without a radiological resolution. An HRCT scan (Fig. 1A ) revealed a disseminated nodular pattern in both lungs, accompanied by peribronchial consolidations and lung parenchyma retraction dominating in the lower lobes. No pleural effusion was seen. Bronchoscopy was unremarkable. A transbronchial biopsy revealed mild nonspecific inflammation with areas of fibrosis in the bronchial walls. Bronchoalveolar lavage was sent for cell count, bacterial and viral culture, and fungal and acid-fast bacillus analysis. Both sputum and bronchoalveolar lavage cultures were positive for achromobacter denitrificans. After a complete diagnostic workup including repeated bacterial and mycobacterial cultures, QuantiFERON1-TB Gold test, blood CMV-PCR, blood aspergillus galactomannan and candida mannan, immunofluorescent staining of bronchoalveolar fluid for Pneumocystis jiroveci, other pulmonary opportunistic infections were ruled out, and a diagnosis of a. denitrificans pneumonia and EVR pulmonary toxicity was made. A 17-day course of piperacillin/tazobactam chosen according to the susceptibility profile (Table 2) , and a reduction of the EVR dose to the target trough levels of 2.8-3.2 ng/ml resulted only in partial resolution of radiological abnormalities confirmed by HRCT (Fig. 1B) . After three weeks of antibiotic treatment EVR was withheld. EVR discontinuation with no additional antibiotic treatment resulted in complete recovery and a complete resolution of pulmonary infiltrates in an HRCT performed at a further 10-week follow-up (Fig. 1C) . The immunosuppressive regimen on discharge was restricted to cyclosporine and glucocorticosteroids. We performed a functional analysis of peripheral blood neutrophils and monocytes using Phagotest and Phagoburst tests (both Glycotope Biotechnology, Germany). Phagotest measures the ability to perform phagocytosis, or specifically the ability of the phagocytes to take up the bacteria, by assessing the level of fluorescence emitted by phagocytes -both monocytes and neutrophils. The fluorescence comes from fluorescently stained bacteria engulfed by the phagocytes. Phagotest was performed in accordance with the manufacturer's protocol and with modifications. The original protocol involves the use of Escherichia coli stained with FITC (fluorescein) only (included in kit). Phagotest was also used for assessing the phagocytosis of a. denitrificans stained with CFDA (carboxyfluorescein diacetate succinimidyl ester). This method was established in our laboratory and described elsewhere [9] . The fluorescence emitted by phagocytes reflects the intensity of the engulfment of bacteria. Apart from using different bacteria, all stages of the manufacturer's manual were performed in the same manner for E. coli and a. denitrificans phagocytosis assessment. Phagoburst measures the ability of phagocytes to effectively kill the bacteria by the oxidative burst. The intensity of oxidative burst is estimated by assessing the conversion of non-fluorescent DHR123 (dihydrorhodamine 123) into green fluorescence-emitting R123 (rhodamine 123) in the presence of reactive oxidants. The higher the fluorescence is, the more intense is the oxidative burst. As in case of Phagotest, the assessment with E. coli (already in the manufacturer's kit) and a. denitrificans isolated from the patient's sputum and bronchoalveolar lavage was performed according to the manufacturer's protocol. The fluorescence intensity was assessed using a FACScan cytometer (BD, USA). Flow cytometry techniques have been extensively used to evaluate phagocyte function. Both Phagotest and Phagoburst have been shown to be useful tests for the evaluation of phagocytosis and oxidative burst activity in different research contexts, providing repeatable and credible results [10] [11] [12] [13] . The ex vivo phagocytic activity ( Fig. 2 ) and intensity of oxidative burst (Fig. 3 ) measured by the mean fluorescent intensity (MFI) of neutrophils and monocytes against E. coli and a. denitrificans were assessed using patients' cells collected on EVR (2.8 ng/ml) and using patient cells collected 3 weeks after EVR discontinuation, and using cells from a healthy control. The phagocytic activity against a. denitrificans and E. coli of patient neutrophils and monocytes collected during EVR treatment was notably lower compared to neu-trophils and monocytes from a healthy control, especially in the case of E. coli. The phagocytic activity of patient neutrophils and monocytes after 3 weeks of EVR absence was higher than patient cell activity in the presence of EVR. The phagocytic activity of patient cells off EVR against a. denitrificans was similar to the activity of healthy controls; however, the activity of patient cells off EVR against E. coli was still below the activity of control cells (Fig. 2) . The level of oxidative burst from neutrophils and monocytes, even more so, obtained from the patient on EVR treatment was significantly lower than the oxidative burst from the healthy control cells. After 3 weeks of EVR absence, the oxidative burst of patient neutrophils engulfing E. coli and a. denitrificans was restored to a level similar to the healthy control, even though the patient continued to receive prednisone and CsA. The level of oxidative burst carried out by patient monocytes was also improved with EVR absence, but still lower by half compared to monocytes of a healthy control (Fig. 3) . To confirm the aforementioned EVR properties we performed a similar assay in vitro using peripheral blood neutrophils and monocytes from a healthy donor. These cells were exposed to four different concentrations of EVR, ranging from 2 to 15 ng/ml (2 ng/ml, 5 ng/ml, 8 ng/ml and 15 ng/ml). The processes of phagocytosis and oxidative burst generation against both a. denitrificans and E. coli were again significantly affected by increasing doses of EVR in a dose-dependent manner (Figs. 4 and 5) . Few animal or in vitro studies have evaluated the pathogenesis of mTOR inhibitor-induced lung toxicities, and the underlying mechanisms remain to be determined. An immunological dose-independent origin is suggested, with three main mechanisms involved. First, mTOR inhibitors might expose cryptic antigens and induce an autoimmune response [14] . Second, a delayed-type hypersensitivity reaction is possible with an mTOR inhibitor as a hapten [15] . Third, pulmonary inflammation could be the consequence of cytokine production alterations caused by mTOR inhibitors. in vitro studies confirm that mTOR inhibitors stimulate the release of a number of proinflammatory cytokines such as interleukin (IL)-12, IL-23, tumor necrosis factor (TNF) and IL-1β while inhibiting the secretion of the anti-inflammatory cytokine IL-10 [15] [16] [17] . Additionally, a dose-related effect -and therefore directly toxic mTOR effect -has been suggested [14, 18] . Washino et al. found in an animal model that treatment with another mTOR inhibitor, temsirolimus, depleted alveolar macrophages in vivo, which, as the authors hypothesized, might lead to an accumulation of surfactant lipids, a condition seen in many respiratory pathologies. Temsirolimus also inhibited macrophage proliferation at lower drug concentrations, whereas it induced cell death in primary cultured alveolar macrophages at higher concentrations in vitro [19] . In another study by Wislez et al. [20] temsirolimus induced apoptosis of intraepithelial macrophages in alveolar epithelial neoplasia in K-rasLA1 mice. Several clinical case reports of EVR-induced lung injury also present macrophage depletion in BAL cell analyses [21, 22] . Observations on the mTOR inhibitor influence on neutrophils and monocytes/macrophages are consistent with our results showing dose-dependent impairment of neutrophil/monocyte phagocytic activity and oxidative burst generation. Fernandez-Botran et al. reported that in patients suffering from community-acquired pneumonia, blood neutrophil functional responses (phagocytosis and phagocytosis-stimulated respiratory burst activity) were elevated as compared to healthy controls [23] . We observed that in our patient with pneumonia blood neutrophil and monocytes functional responses were significantly reduced after exposure to EVR, as demonstrated by ex vivo assays. It is known that alveolar macrophages are major effector cells in initiating and orchestrating the respiratory immune response to infectious agents. Alveolar macrophage depletion and inadequate alveolar macrophage function may result in an increase in pulmonary surfactants, but also affect the resolution of tissue inflammation, leading to collateral damage. Macrophage-depleted mice showed both higher concentrations of intrapulmonary cytokines, with greater numbers of activated polymorphonuclear cells, and accumulation of apoptotic and secondary necrotic neutrophils when compared to control mice [24] . achromobacter denitrificans is a gram-negative, mobile, strictly aerobic, ubiquitous, nonglucosefermenting , oxidase-and catalase-positive bacterium present in soil and water [25] . This bacterium only rarely causes human infections. Most of the infections by achromobacter are asymptomatic. The symptomatic infections usually occur in immunodeficient patients and include cases of bacteriemia, natural valve or prosthetic valve endocarditis, meningitis, pneumonia, peritonitis, conjunctivitis, osteomyelitis, intra-abdominal abscess, and prosthesis infections [26] . Therefore, the observed a. denitrificans pneumonia was probably a superimposed phenomenon resulting from the same, as in the case of mTOR-related pneumonitis and impaired function of neutrophils and monocytes/macrophages. Given the presented clinical scenario it is difficult to clearly distinguish between the relative contributions of infection and possible EVR toxicity. Other cases of opportunistic pulmonary infections, Pneumocystis jiroveci pneumonia and invasive pulmonary aspergillosis, mimicking typical pulmonary adverse noninfectious mTOR inhibitor-induced pneumonitis and cryptogenic organizing pneumonia, have been reported previously in both EVR and temsirolimus treated patients [6] [7] [8] . In all three cases the identification of opportunistic pathogens in both bronchoalveolar lavage and biopsy specimens was an unexpected finding. Pneumocystis jiroveci infection induced only mild chronic inflammation assessed by bronchoalveolar lavage fluid analysis, and the authors concluded that the paucity of inflammatory reaction could result from immunosuppression due to cancer recurrence or glucocorticosteroid treatment [6] . This could also reflect the impaired function of neutrophils and monocytes/macrophages. In a large phase III clinical trial program of EVR the incidence of interstitial lung disease was 0.4%. In three of the four heart Tx recipients the discontinuation of EVR resulted in interstitial lung disease improvement or resolution, while there was no improvement in a patient who continued to receive EVR. The outcome was fatal in the KTx recipient, in whom EVR therapy was continued and in the liver Tx recipient despite EVR discontinuation, probably due to a superimposed infection. After having analyzed the available literature, the authors concluded that prompt discontinuation of mTOR inhibitor therapy as soon as interstitial lung disease is diagnosed is crucial to ensure a favorable outcome [27] . Withdrawal of immunosuppression is a key component of treating infections in immunocompromised patients. However, the neutrophil and monocyte/macrophage function clearly improved after withdrawing EVR, even though the patient was still maintained on prednisolone and cyclosporine. The in vitro dose-dependent impairment of a healthy volunteer's neutrophil/monocyte functional responses also would suggest direct EVR toxicity. This is in agreement with a study by Solazzo et al., which reported a relationship of interstitial lung disease to EVR trough concentration > 9.03 ng/ml in a group of 500 KTx recipients on an EVR and CsA combined protocol [28] . In conclusion, the present report is the first to suggest dose-dependent impairment of neutrophil/monocyte functional responses such as phagocytic activity and oxidative burst generation, as possible mechanisms of mTOR associated pulmonary toxicity. The phenomenon described provides one possible explanation; however, more rigorous investigation is needed to define the exact biological machinery associated with this clinical condition. Bioethics Committee of the Medical University of Gdańsk approval no. NKBBN/195/2018. One of the authors (A.D.) provided a blood sample as a healthy control after providing written informed consent. Written informed consent was obtained from the patient for publication of this case report and all accompanying images. All data containing relevant information to support the findings is included in the manuscript. There are no data sheets related to this case report. This work was supported by the Polish Committee for Scientific Research via the Medical University of Gdansk . The funder had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. Reduced incidence of cytomegalovirus infection in kidney transplant recipients receiving everolimus and reduced tacrolimus doses Everolimus leads to a lower risk of BKV viremia than mycophenolic acid in de novo renal transplantation patients: a single-center experience Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitors Brief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients Diffuse alveolar hemorrhage induced by everolimus Spontaneous resolution of Pneumocystis jirovecii pneumonia on high-resolution computed tomography in a patient with renal cell carcinoma A case of pneumocystis pneumonia associated with everolimus therapy for renal cell carcinoma Invasive pulmonary aspergillosis mimicking organizing pneumonia after mTOR inhibitor therapy: a case report The high PMNs phagocytosis resistance of enterococcal isolates from RTx patients Phagocytosis: measurement by flow cytometry Repeatability of flow cytometric and classical measurement of phagocytosis and respiratory burst in bovine polymorphonuclear leukocytes Long-term immunosuppression in burned patients assessed by in vitro neutrophil oxidative burst (Phagoburst) Altered neutrophil functions in elderly patients during a 6-month follow-up period after a hip fracture Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients Sirolimus-associated pulmonary toxicity Mammalian target of rapamycin (mTOR) orchestrates the defense program of innate immune cells The multifunctional role of mTOR in innate immunity: implications for transplant immunity Chamienia A 405 Daca A 405 JE 375 Nędzi-Góra M Pępek M 121 Pierzyna-Świtała M 365 Porebski G 398 Pukajło-Marczyk A 199 Radomska-Leśniewska DM 105 Ramonaite A 401 Ritterbusch H 244 Sánchez Monroy V 76 Słotwińska SM 99 Urbańczyk A 210 Urosevic I 54 Volokha A 250 von Bernuth H 244 We sincerely thank all health care workers who contributed to management of this patient including the micro-biology and immunology teams, and all who helped us to publish the case report.